Methods for treating cancer using bispecific anti-CD3xMUC16 and anti-CTLA-4 antibodies
Combining CTLA-4 and bispecific MUC16/CD3 antibodies synergistically activates T cells to treat ovarian cancer, addressing treatment resistance and recurrence, and enhancing survival without inducing cytokine storms.
Patent Information
- Application Number
- JP2024531049
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-24
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a high unmet need for effective therapies against ovarian cancer, as current treatments often fail to prevent recurrence and are ineffective against resistant tumors, and existing immunotherapies targeting CTLA-4 and PD-1 pathways have distinct but redundant mechanisms, limiting their combined efficacy.
A method involving the administration of a therapeutically effective amount of an antibody that specifically binds to CTLA-4 in combination with a bispecific antibody that binds to MUC16 and CD3, administered sequentially or simultaneously, to enhance T cell function and target ovarian cancer cells.
This approach enhances tumor inhibition, delays recurrence, and increases survival by synergistically activating T cells, overcoming resistance to conventional therapies and reducing cytokine release syndrome.
Smart Images

Figure 2024542536000001 
Figure 2024542536000002 
Figure 2024542536000003
Abstract
Description
[Technical field]
[0001] Sequence Listing Reference This application incorporates by reference a computer readable sequence listing in ST.26 XML format, entitled 11047WO01-Sequence, created on November 23, 2022, and containing 54,045 bytes.
[0002] The present invention relates to a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody that specifically binds to the immunomodulatory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), in combination with a bispecific antibody that binds mucin 16 (MUC16) and CD3. [Background technology]
[0003] Mucin 16 (MUC16), also known as cancer antigen 125, carcinoma antigen 125, carbohydrate antigen 125, or CA-125, is a single transmembrane domain, highly glycosylated integral membrane glycoprotein that is highly expressed in ovarian cancer. MUC16 is composed of three major domains: an extracellular N-terminal domain, a large tandem repeat domain interspersed with sea urchin sperm, enterokinase, and agrin (SEA) domains, and a carboxyl-terminal domain that contains a segment of the transmembrane region and a short cytoplasmic tail. Proteolytic cleavage releases much of the extracellular portion of MUC16 into the bloodstream. MUC16 is overexpressed in cancers including ovarian cancer, breast cancer, pancreatic cancer, non-small cell lung cancer, intrahepatic cholangiocarcinoma mass-forming type, adenocarcinoma of the cervix, and adenocarcinoma of the gastric tract, as well as diseases and conditions including inflammatory bowel disease, liver cirrhosis, heart failure, peritoneal infection, and abdominal surgery. (Haridas, D. et al., 2014, FASEB J., 28:4183-4199). Expression on cancer cells has been shown to protect tumor cells from the immune system. (Felder, M. et al., 2014, Molecular Cancer, 13:129) Methods for treating ovarian cancer using antibodies against MUC16 are being investigated. Oregovomab and abgovomab are anti-MUC16 antibodies with limited success. (Felder, Das, S. and Batra, SK 2015, Cancer Res. 75:4660-4674, supra.)
[0004] CD3 is a homodimeric or heterodimeric antigen expressed on T cells in association with the T cell receptor complex (TCR) and is required for T cell activation. Functional CD3 is formed from the dimeric association of two of four different chains: epsilon, zeta, delta, and gamma. CD3 dimeric configurations include gamma / epsilon, delta / epsilon, and zeta / zeta. Antibodies against CD3 have been shown to cluster CD3 on T cells, thereby triggering T cell activation in a manner similar to TCR engagement by peptide-loaded MHC molecules. Thus, anti-CD3 antibodies have been proposed for therapeutic purposes, including T cell activation. Furthermore, bispecific antibodies capable of binding CD3 and a target antigen have been proposed for therapeutic uses, including targeting T cell immune responses to tissues and cells expressing the target antigen.
[0005] Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152) is a type I transmembrane T-cell inhibitory checkpoint receptor expressed on conventional and regulatory T cells. CTLA-4 negatively regulates T-cell activation by outcompeting the stimulatory receptor CD28 from binding to its natural ligands B7-1 (CD80) and B7-2 (CD86). Initial T-cell activation is achieved by stimulating the T-cell receptor (TCR), which recognizes specific peptides presented by major histocompatibility complex class I or II (MHCI or MHCII) proteins on antigen-presenting cells (APCs) (Goldrath et al. 1999, Nature 402:255-262). The activated TCR then initiates a cascade of signaling events that can be monitored by the expression of transfected reporter genes driven by promoters that regulate the expression of various transcription factors such as activation protein 1 (AP-1), nuclear factor of activated T cells (NFAT), or nuclear factor kappa light-chain-enhancer of activated B cells (NFκB). The T cell response is then further refined through the engagement of costimulatory or co-inhibitory receptors constitutively or inducibly expressed on T cells, such as CD28, CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), LAG-3 (lymphocyte activation gene 3), or other molecules (Sharpe et al. 2002, Nat. Rev. Immunol. 2:116-126).
[0006] Programmed death-1 (PD-1) receptor signaling in the tumor microenvironment plays a key role in enabling tumor cells to escape immunosurveillance by the host immune system. Blockade of the PD-1 signaling pathway has demonstrated clinical activity in patients with multiple tumor types, and antibody therapeutics that block PD-1 (e.g., nivolumab and pembrolizumab) have been approved for the treatment of, for example, metastatic melanoma and metastatic squamous non-small cell lung cancer. Recent data have demonstrated clinical activity of PD-1 blockade in patients with aggressive NHL and Hodgkin's lymphoma (Lesokhin, et al. 2014, Abstract 291, 56th ASH Annual Meeting and Exposition, San Francisco, Calif.; Ansell et al. 2015, N. Engl. J. Med. 372(4):311-9).
[0007] Ovarian cancer is the most lethal of gynecologic malignancies. Although the estimated number of new cases of ovarian cancer in U.S. women is much lower than certain other cancers, the mortality-to-morbidity ratio of ovarian cancer is quite high (Siegal et al., CA Cancer J Clin 66:7-30, 2016). Ovarian cancer is often diagnosed at an advanced stage, which contributes to its lethality. The current standard of care for ovarian cancer is surgery followed by chemotherapy, i.e., a combination of platinum-based drugs and taxanes. While the majority of patients respond to initial treatment, most patients experience disease recurrence, resulting in cycles of repeated surgery and additional rounds of chemotherapy. Although recurrent ovarian cancers can respond to further treatments, nearly all of them eventually become resistant to currently available therapies. Despite recent advances in therapy, such as PARP inhibitors for patients with BRCA or other homologous recombination defect (HRD) mutations, advanced ovarian cancer remains a disease of high unmet need.
[0008] Evidence suggests that ovarian cancer may be amenable to some immunotherapy (Kandalaft et al., J. Clin. Oncol., 29:925-933, 2011). For example, tumors expressing intraepithelial CD8 + Ovarian cancer patients who were positive for T lymphocyte infiltration had intraepithelial CD8 + They had significantly better overall survival and progression-free survival than patients without T-lymphocyte infiltration (Hamanishi et al., PNAS, 104:3360-65, 2007, and Zhang et al., N. Engl. J. Med., 348:203-213, 2003). Furthermore, some patients exhibit an innate immune response to the tumor, as demonstrated by the detection of tumor-reactive T cells and antibodies in the blood, tumor, or ascites of patients with advanced disease (Schliengar et al., Clin Cancer Res, 9:1517-1527, 2003).
[0009] An open question is whether the anti-tumor immune response induced by anti-CTLA-4 and anti-PD-1 antibodies is mediated through distinct, non-overlapping mechanisms. Many studies have demonstrated that CTLA-4 and PD-1 attenuate T cell activation through distinct mechanisms (Pardoll, Nat. Rev. Cancer, 12:252-264, 2012). CTLA-4 is upregulated immediately after TCR ligation and outcompetes CD28 for B7 ligand binding, thus attenuating positive co-stimulation by CD28 (Krummel and Allison, J. Exp. Med., 182:459-465, 1995; Walunas et al., Immunity, 1:405-413, 1994). PD-1 is induced late during T cell activation and, upon engagement with PD-L1 or PD-L2, attenuates TCR signaling through recruitment of tyrosine phosphatases. In addition to utilizing distinct mechanisms of action, CTLA-4 and PD-1 attenuate T cell activity through spatially and temporally separated mechanisms. CTLA-4 primarily attenuates T cell activation at the priming stage through cell-intrinsic and -extrinsic mechanisms, whereas PD-1 attenuates T cell activity in peripheral tissues primarily through cell-intrinsic mechanisms (Pardoll, Id.; Walker and Sansom, Nat Rev Immunol., 11(12):852-853, 2011). This difference is highlighted by the fact that the cellular sources of the ligands for PD-1 and CTLA-4 are distinct and serve distinct physiological functions (Wei, Cell, 170(6):1120-1133, 2017). Blockade of the PD-1 signaling pathway has shown some clinical activity in patients with multiple tumor types. Anti-PD-1 antibody therapy is the focus of clinical combination therapy with various modalities, including bispecific antibodies for the treatment of ovarian cancer.
[0010] Given the continuing high unmet need for effective therapies for ovarian cancer, as demonstrated herein, it may be useful to combine agents to enhance T cell function (e.g., CTLA-4 inhibitors such as anti-CTLA-4 antibodies) with treatment with agents against the target antigen (bispecific anti-MUC16 / anti-CD3 antibodies). Summary of the Invention
[0011] According to certain embodiments, the present invention provides a method for treating, ameliorating, or inhibiting the growth of at least one symptom or sign of a MUC16-expressing cancer in a subject. The method according to this aspect of the invention comprises administering to a subject in need thereof a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), in combination with a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that specifically binds MUC16 and CD3.
[0012] Certain embodiments of the invention provide methods of treating, ameliorating, or inhibiting the growth of at least one symptom or sign of a MUC16-expressing cancer in a subject. Certain embodiments of the invention provide methods of slowing tumor growth or preventing tumor recurrence. Methods according to this and other aspects of the invention include sequentially administering to a subject in need thereof one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds CTLA-4 in combination with one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds MUC16 and CD3.
[0013] In one aspect, the invention provides a method of treating or inhibiting the growth of a MUC16-expressing tumor, the method comprising administering to a subject in need thereof (a) a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and (b) a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3. Optionally, the anti-CTLA-4 antibody is administered before, simultaneously with, or after the bispecific antibody. Optionally, the anti-CTLA-4 antibody is administered before the bispecific antibody. Optionally, the anti-CTLA-4 antibody is administered after the bispecific antibody. Optionally, one or more doses of the anti-CTLA-4 antibody are administered in combination with one or more doses of the bispecific antibody. Optionally, the anti-CTLA-4 antibody is administered at a dose of 0.1 mg / kg to 20 mg / kg of the subject's body weight. In some cases, the anti-CTLA-4 antibody is administered at a dose of 10 mg to 1500 mg (e.g., 20 mg to 250 mg). In some cases, the bispecific antibody is administered at a dose of 0.1 mg / kg to 20 mg / kg of the subject's body weight. In some cases, the bispecific antibody is administered at a dose of 10 mg to 1500 mg (e.g., 30 mg to 900 mg). In some cases, each subsequent dose of the anti-CTLA-4 antibody is administered 0.5 weeks to 12 weeks after the immediately preceding dose. In some cases, each subsequent dose of the bispecific antibody is administered 0.5 weeks to 12 weeks after the immediately preceding dose. In various embodiments, the antibody is administered intravenously, subcutaneously, or intraperitoneally.
[0014] In some embodiments, the tumor is selected from ovarian cancer, ovarian serous carcinoma, breast cancer, invasive lobular breast cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, bladder cancer, or non-small cell lung cancer. In some embodiments, the tumor comprises ovarian cancer. In some embodiments, the tumor comprises ovarian serous carcinoma. In some embodiments, the subject is resistant to or has responded inadequately to, or subsequently relapsed from, a previous therapy.
[0015] In some cases, the method further comprises administering a third therapeutic agent or therapy to the subject. In some embodiments, the third therapeutic agent or therapy is selected from the group consisting of radiation, surgery, a chemotherapeutic agent, a cancer vaccine, a PD-1 inhibitor, a PD-L1 inhibitor, a LAG-3 inhibitor, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist, an angiopoietin-2 (Ang2) inhibitor, a transforming growth factor beta (TGF.beta.) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, an antibody against a tumor-specific antigen, a Bacillus Calmette-Guerin vaccine, a granulocyte-macrophage colony-stimulating factor, a cytotoxin, an interleukin-6 receptor (IL-6R) inhibitor, an interleukin-4 receptor (IL-4R) inhibitor, an IL-10 inhibitor, IL-2, IL-7, IL-21, IL-15, an antibody drug conjugate, an anti-inflammatory drug, and a dietary supplement.
[0016] In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof is selected from ipilimumab and REGN4659. In some embodiments, the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR1, HCDR2, and HCDR3) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 34. In some embodiments, HCDR1 comprises the amino acid sequence of SEQ ID NO: 35, HCDR2 comprises the amino acid sequence of SEQ ID NO: 36, HCDR3 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 40. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 33, and a LCVR comprising the amino acid sequence of SEQ ID NO: 34. In some embodiments, the anti-CTLA-4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:41 and a light chain comprising the amino acid sequence of SEQ ID NO:42.
[0017] In some embodiments, the first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, A-HCDR1 comprises the amino acid sequence of SEQ ID NO: 8, A-HCDR2 comprises the amino acid sequence of SEQ ID NO: 9, A-HCDR3 comprises the amino acid sequence of SEQ ID NO: 10, A-LCDR1 comprises the amino acid sequence of SEQ ID NO: 11, A-LCDR2 comprises the amino acid sequence of SEQ ID NO: 12, and A-LCDR3 comprises the amino acid sequence of SEQ ID NO: 13. In some embodiments, the bispecific antibody comprises an A-HCVR comprising the amino acid sequence of SEQ ID NO: 1, and an A-LCVR comprising the amino acid sequence of SEQ ID NO: 2.
[0018] In some embodiments, the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4, 5, 6, and 7, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising an amino acid sequence of SEQ ID NO: 2. In some embodiments, B-HCDR1, B-HCDR2, and B-HCDR3 comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-15-16, 17-18-19, 20-21-22, 23-24-25, and 26-27-28, respectively, and B-LCDR1, B-LCDR2, and B-LCDR3 comprise an amino acid sequence of SEQ ID NOs: 11-12-13, respectively. In some cases, the second antigen-binding arm comprises a B-HCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NO:3, 4, 5, 6, and 7, and a B-LCVR comprising the amino acid sequence of SEQ ID NO:2.
[0019] In some embodiments, the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:3, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:2.
[0020] In some embodiments, the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:4, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:2.
[0021] In some embodiments, the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:5, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:2.
[0022] In some embodiments, the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:6, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:2.
[0023] In some embodiments, the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:7, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:2.
[0024] In some embodiments, the anti-CTLA-4 antibody, the bispecific antibody, or both, comprise a human IgG1 or IgG4 heavy chain constant region.
[0025] In another aspect, the invention provides a method of treating or inhibiting the growth of a MUC16-expressing tumor, the method comprising administering to a subject in need thereof (a) a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and (b) a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, wherein (a) the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 34. (b) a first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO: 2; and (c) a second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 3 and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO: 2.
[0026] In some embodiments of the methods, the anti-CTLA-4 antibody and the bispecific antibody each comprise: (a) HCDR1 comprises the amino acid sequence of SEQ ID NO: 35, HCDR2 comprises the amino acid sequence of SEQ ID NO: 36, HCDR3 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 40; (b) A-HCDR1 comprises the amino acid sequence of SEQ ID NO: 8, A-HCDR2 comprises the amino acid sequence of SEQ ID NO: 9, and A-HCDR3 comprises (c) A-LCDR1 comprises the amino acid sequence of SEQ ID NO: 14, B-HCDR2 comprises the amino acid sequence of SEQ ID NO: 15, and B-HCDR3 comprises the amino acid sequence of SEQ ID NO: 16, B-LCDR1 comprises the amino acid sequence of SEQ ID NO: 11, B-LCDR2 comprises the amino acid sequence of SEQ ID NO: 12, and B-LCDR3 comprises the amino acid sequence of SEQ ID NO: 13.
[0027] In some embodiments of the methods, the anti-CTLA-4 antibody and the bispecific antibody each comprise: (a) the HCVR comprises the amino acid sequence of SEQ ID NO: 33 and the LCVR comprises the amino acid sequence of SEQ ID NO: 34; (b) the A-HCVR comprises the amino acid sequence of SEQ ID NO: 1 and the A-LCVR comprises the amino acid sequence of SEQ ID NO: 2; and (c) the B-HCVR comprises the amino acid sequence of SEQ ID NO: 3 and the B-LCVR comprises the amino acid sequence of SEQ ID NO: 2.
[0028] In some embodiments of the method, the anti-CTLA-4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:41 and a light chain comprising the amino acid sequence of SEQ ID NO:42, a first antigen-binding arm of the bispecific antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:30, and a second antigen-binding arm of the bispecific antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:31 and a light chain comprising the amino acid sequence of SEQ ID NO:30.
[0029] In various embodiments of the methods described above or discussed herein, administration of the anti-CTLA4 antibody or antigen-binding fragment thereof and / or bispecific antibody does not cause a significant increase in serum cytokine levels compared to a control (e.g., an isotype control). Thus, administration of a combination of an anti-CTLA4 antibody (or fragment thereof) and a bispecific antibody to treat MUC16-expressing cancer can be performed without inducing cytokine release syndrome in subjects administered the combination therapy. In some cases, administration of the anti-CTLA4 antibody or antigen-binding fragment thereof and bispecific antibody results in an increase in serum cytokine levels in no more than 5% of subjects compared to an isotype control at 4 hours after administration. In some cases, administration of the anti-CTLA4 antibody or antigen-binding fragment thereof and bispecific antibody results in an increase in serum cytokine levels in no more than 4%, no more than 3%, no more than 2%, or no more than 1% of subjects compared to an isotype control at 4 hours after administration.
[0030] In some embodiments, the antibodies discussed herein are used in the manufacture of a medicament for use in any of the methods discussed above or herein. In some embodiments, the antibodies discussed herein are for use in medicine or for use in the treatment of cancer, as discussed above or herein. For example, the present disclosure includes: (A) use of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, in combination with an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), in the manufacture of a medicament for treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof; (B) use of an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3 in the manufacture of a medicament for treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof; (C) Use of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, in combination with an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), in the manufacture of a medicament for treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof, wherein (i) the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR1, HCDR2, and HCDR3) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and HCDR3) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 34. (ii) a first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO: 2; and (iii) a second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 3 and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO: 2. (D) Use of an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, in the manufacture of a medicament for treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof, wherein (i) the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and HCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 34. (ii) a first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO: 2; and (iii) a second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 3 and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO: 2. (E) A bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, in combination with an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), for use in treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof. (F) An antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, for use in treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof. (G) A bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, in combination with an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), for use in treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof, wherein (i) the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR1, HCDR2, and HCDR3) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 34. (ii) a first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO: 2; and (iii) a second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 3 and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO: 2; (H) An antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, for use in treating or inhibiting the growth of a MUC16-expressing tumor in a subject in need thereof, wherein: (i) the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 34; (ii) an antibody or antigen-binding fragment thereof, wherein the first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO: 2; and (iii) a second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 3 and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO: 2.
[0031] In various embodiments, any of the features or components of the embodiments described above or discussed herein may be combined, and such combinations are encompassed within the scope of the present disclosure. Any specific value described above or discussed herein may be combined with another associated value described above or discussed herein to recite a range having values representing the upper and lower limits of the range, and such ranges are encompassed within the scope of the present disclosure.
[0032] Other embodiments of the invention will become apparent from consideration of the detailed description that follows. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0033] Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, as such methods and conditions may vary. It should also be understood that the terms used herein are used for the purpose of describing only specific embodiments, and are not intended to be limiting, since the scope of the present invention is limited only by the scope of the appended claims. Any embodiment or feature of the embodiment can be combined with each other, and such combinations are expressly included within the scope of the present invention. Any specific value discussed above or herein may be combined with another related value discussed above or herein to recite a range having values representing the upper and lower limits of the range, and such ranges are included within the scope of the present disclosure.
[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.As used herein, the term "about" when used in relation to a specific referenced numerical value means that the value may vary by 1% or less from the referenced value.For example, as used herein, the expression "about 100" includes 99 and 101, and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0035] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications, and non-patent publications mentioned herein are incorporated by reference in their entirety.
[0036] Methods for Treating or Inhibiting Cancer The present invention includes methods for treating, ameliorating, or reducing the severity of at least one symptom or sign, or inhibiting the growth of cancer (e.g., a MUC16-expressing cancer) in a subject. The method according to this aspect of the invention includes administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to CTLA-4, in combination with a therapeutically effective amount of a bispecific antibody against MUC16 and CD3. As used herein, the terms "treat," "treating," and the like, mean alleviating a symptom, eliminating the cause of a symptom, either temporarily or permanently, slowing or inhibiting tumor growth, reducing tumor cell or tumor burden, promoting tumor regression, causing tumor shrinkage, necrosis, and / or disappearance, preventing tumor recurrence, and / or increasing the survival of a subject.
[0037] As used herein, the phrase "subject in need thereof" refers to a human or non-human mammal exhibiting one or more symptoms or signs of cancer, and / or a human or non-human mammal diagnosed with cancer, including ovarian cancer, and in need of treatment for cancer. In many embodiments, the term "subject" may be used interchangeably with the term "patient." For example, a human subject may be diagnosed with a primary or metastatic tumor and / or with one or more symptoms or signs, including, but not limited to, enlarged lymph nodes, abdominal bloating, chest pain / tightness, unexplained weight loss, fever, night sweats, persistent fatigue, loss of appetite, enlarged spleen, and itching. This phrase includes a subject with a primary or established ovarian tumor. In specific embodiments, this phrase includes a human subject with ovarian cancer or another tumor expressing MUC16 and in need of treatment thereof. In other specific embodiments, this phrase includes a subject with a MUC16+ tumor (e.g., a tumor with MUC16 expression as determined by flow cytometry). In certain embodiments, the term "subject in need thereof" includes patients with ovarian cancer that is resistant or refractory to previous therapy (e.g., treatment with conventional anti-cancer drugs) or not adequately controlled by previous therapy. For example, the term includes subjects treated with chemotherapy, such as platinum-based chemotherapy agents (e.g., cisplatin) or taxol compounds (e.g., docetaxel). The term also includes subjects with ovarian tumors for which conventional anti-cancer therapy is not advisable, for example, due to toxic side effects. For example, the term includes patients who have undergone one or more cycles of chemotherapy with toxic side effects. In certain embodiments, the term "subject in need thereof" includes patients with ovarian cancer that have been treated but have subsequently recurred or metastasized. For example, patients with ovarian cancer who have been treated with one or more anti-cancer drugs and may have undergone tumor regression, but who subsequently recur with cancer that is resistant to one or more anti-cancer drugs (e.g., chemotherapy-resistant cancer), are treated with the methods of the present invention.
[0038] The term "subject in need thereof" also includes subjects at risk of developing ovarian cancer, such as those with a family history of ovarian cancer, those with a past medical history of an infection associated with ovarian cancer, those with a mutation in the BRCA1 / 2 gene, or those with a compromised immune system due to HIV infection or immunosuppressant medications. In certain embodiments, the methods of the invention are used in subjects with ovarian cancer.
[0039] The terms "tumor," "cancer," and "malignant tumor" are used interchangeably herein. As used herein, the term "ovarian cancer" refers to tumors of the ovaries and fallopian tubes, and includes serous carcinoma, endometrioid carcinoma, clear cell carcinoma, and mucinous carcinoma.
[0040] According to certain embodiments, the invention includes a method for treating a tumor or slowing or inhibiting the growth of a tumor. In certain embodiments, the invention includes a method for promoting tumor regression. In certain embodiments, the invention includes a method for reducing tumor cell burden or reducing tumor burden. In certain embodiments, the invention includes a method for preventing tumor recurrence. The method according to this aspect of the invention includes sequentially administering to a subject in need thereof a therapeutically effective amount of an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody, each antibody being administered to the subject in multiple doses, e.g., as part of a particular therapeutic dosing regimen. For example, the therapeutic dosing regimen may include administering one or more doses of an anti-CTLA-4 antibody to a subject approximately once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every two months, once every three months, once every four months, or less frequently. In certain embodiments, one or more doses of an anti-CTLA-4 antibody are administered in combination with one or more therapeutically effective doses of a bispecific anti-MUC16 / anti-CD3 antibody, and the one or more doses of the bispecific antibody are administered to a subject approximately once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every two months, once every three months, once every four months or less frequently.
[0041] In certain embodiments, each dose of anti-MUC16 / anti-CD3 antibody is administered in more than one portion, e.g., 2-5 portions ("split doses"), within a given administration period. Anti-MUC16 / anti-CD3 bispecific antibodies may be administered in split doses to reduce or eliminate the cytokine "spike" induced in response to administration of the antibody. Cytokine spike refers to the clinical symptoms of cytokine release syndrome ("cytokine storm") and infusion-related reactions. In certain embodiments, the methods of the invention comprise administering to a subject in need thereof one or more doses of an anti-CTLA-4 antibody in combination with one or more doses of a bispecific anti-MUC16 / anti-CD3 antibody, the dose of the bispecific antibody being administered as a split dose or more than one portion, e.g., 2, 3, 4, or 5 portions, within a given administration period. In certain embodiments, the dose of the bispecific antibody is split into two or more portions, each portion containing an equal amount of antibody as the other portions. For example, a dose of anti-MUC16 / anti-CD3 antibody comprising 1000 micrograms may be administered once a week, the dose being administered in two portions within the week, each portion comprising 500 micrograms. In certain embodiments, a dose of a bispecific antibody is administered in two or more portions, the portions comprising unequal amounts of antibody, e.g., more or less than the first portion. For example, a dose of anti-MUC16 / anti-CD3 antibody comprising 1000 micrograms may be administered once a week, the dose being administered in two portions within the week, the first portion comprising 700 micrograms and the second portion comprising 300 micrograms. As another example, a dose of anti-MUC16 / anti-CD3 antibody comprising 1000 micrograms may be administered once every two weeks, the dose being administered in three portions within the two weeks, the first portion comprising 400 micrograms, the second portion comprising 300 micrograms and the third portion comprising 300 micrograms.
[0042] In certain embodiments, the invention includes a method of inhibiting, slowing, or stopping tumor metastasis or tumor invasion into peripheral organs. According to this aspect, the method comprises administering to a subject in need thereof a therapeutically effective amount of an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody.
[0043] In a specific embodiment, the invention provides a method for increasing anti-tumor efficacy or increasing tumor inhibition. According to this aspect of the invention, the method comprises administering to a subject having ovarian cancer a therapeutically effective amount of an anti-CTLA-4 antibody followed by a therapeutically effective amount of a bispecific anti-MUC16 / anti-CD3 antibody, where the anti-CTLA-4 antibody can be administered about 1 day, more than 1 day, more than 2 days, more than 3 days, more than 4 days, more than 5 days, more than 6 days, more than 7 days, or more than 8 days prior to the bispecific antibody. In certain embodiments, the method provides an increase in tumor inhibition of, for example, about 20%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, or more than 80%, compared to a subject administered the bispecific antibody prior to the anti-CTLA-4 antibody.
[0044] In certain embodiments, the methods of the invention comprise administering to a subject with ovarian cancer a therapeutically effective amount of an anti-CTLA-4 antibody and a therapeutically effective amount of a bispecific anti-CD3xMUC16 antibody. In specific embodiments, the ovarian cancer is a serous carcinoma. In further embodiments, the ovarian cancer is indolent or aggressive. In certain embodiments, the subject is unresponsive to a previous therapy or has relapsed after a previous therapy. In certain embodiments, the methods of the invention further comprise administering to the subject an additional therapeutic agent.
[0045] In certain embodiments, the methods of the invention comprise administering a therapeutically effective amount of a bispecific anti-MUC16 / anti-CD3 antibody to a subject with a MUC16+ cancer. In specific embodiments, the cancer is ovarian cancer. In further embodiments, the ovarian cancer is indolent or aggressive. In some embodiments, the cancer is platinum-resistant ovarian cancer. In some embodiments, the cancer is taxol-resistant ovarian cancer. In some embodiments, the cancer is fallopian tube cancer. In some embodiments, the cancer is primary peritoneal cancer, and optionally, the patient has elevated levels of serum CA-125. In specific embodiments, the cancer is pancreatic cancer (e.g., pancreatic adenocarcinoma). In certain embodiments, the subject is unresponsive to previous therapy or has relapsed after previous therapy (e.g., chemotherapy). In certain embodiments, the methods of the invention comprise administering an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody to a subject in need thereof as a "first line" treatment (e.g., initial treatment).
[0046] In other embodiments, the anti-CTLA-4 antibody in combination with the bispecific anti-MUC16 / anti-CD3 antibody is administered as a "second line" treatment (e.g., after previous therapy). For example, the anti-CTLA-4 antibody in combination with the bispecific anti-MUC16 / anti-CD3 antibody is administered as a "second line" treatment to a subject who has relapsed after previous therapy, e.g., with chemotherapy.
[0047] In certain embodiments, the methods of the invention are used to treat patients with MRD-positive disease. Minimal residual disease (MRD) refers to a small number of cancer cells remaining in a patient during or after treatment, who may or may not show symptoms or signs of disease. Such residual cancer cells, if not removed, often lead to disease recurrence. The invention includes methods of inhibiting and / or removing residual cancer cells in a patient upon MRD testing. MRD can be assayed according to methods known in the art (e.g., MRD flow cytometry). According to this aspect of the invention, the method includes administering an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody to a subject in need thereof.
[0048] According to certain embodiments, the methods of the invention comprise administering to a subject a therapeutically effective amount of each of an anti-CTLA-4 antibody and a bispecific anti-MUC16 / anti-CD3 antibody in combination with a third therapeutic agent. Examples of the third therapeutic agent include radiation, chemotherapy, surgery, cancer vaccines, PD-1 inhibitors (e.g., anti-PD-1 antibodies), PD-L1 inhibitors (e.g., anti-PD-L1 antibodies), LAG3 inhibitors (e.g., anti-LAG3 antibodies), TIM3 inhibitors, BTLA inhibitors, TIGIT inhibitors, CD47 inhibitors, indoleamine-2,3-dioxygenase (IDO) inhibitors, vascular endothelial growth factor (VEGF) antagonists, Ang2 inhibitors, transforming growth factor beta (TGF.beta.) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, antibodies against tumor-specific antigens (e.g., CA9, CA125, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin-1, MART-1, and CA19-9), vaccines (e.g., Bacillus Calmette-Guerin), granulocyte macrophage colony stimulating factor, cytotoxins, chemotherapeutic agents, cytokines such as IL-6R inhibitors, IL-4R inhibitors, IL-10 inhibitors, IL-2, IL-7, IL-21, and IL-15, anti-inflammatory agents such as corticosteroids and nonsteroidal anti-inflammatory drugs, and nutritional supplements such as antioxidants. In certain embodiments, the antibody may be administered in combination with a therapy including a chemotherapeutic agent (e.g., paclitaxel, carboplatin, doxorubicin, cyclophosphamide, cisplatin, gemcitabine, or docetaxel), radiation, and surgery. As used herein, the phrase "in combination with" means that the antibody is administered to the subject simultaneously with, immediately before, or immediately after administration of a third therapeutic agent. In certain embodiments, the third therapeutic agent is administered as a co-formulation with the antibody. In a related embodiment, the invention includes a method comprising administering a therapeutically effective amount of an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody to a subject undergoing a background anti-cancer treatment regimen, which may include, for example, administration of a course of chemotherapy agents, or radiation.The anti-CTLA-4 antibody in combination with the bispecific anti-MUC16 / anti-CD3 antibody may be added on top of a background anti-cancer treatment regimen. In some embodiments, the antibody is added as part of a "background step-down" scheme, where the background anti-cancer therapy is gradually withdrawn from the subject over time (e.g., in a stepwise manner) while the antibody is administered to the subject at a constant dose, or at increasing or decreasing doses over time.
[0049] In certain embodiments, the methods of the invention comprise administering a therapeutically effective amount of an anti-CTLA-4 antibody in combination with a therapeutically effective amount of a bispecific anti-MUC16 / anti-CD3 antibody to a subject in need thereof, where administration of the antibodies leads to increased inhibition of tumor growth. In certain embodiments, tumor growth is inhibited by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, or about 80% compared to untreated subjects or subjects administered either antibody as monotherapy. In certain embodiments, administration of the anti-CTLA-4 antibody and / or the bispecific anti-MUC16 / anti-CD3 antibody leads to increased tumor regression, tumor shrinkage, and / or elimination. In certain embodiments, administration of an anti-CTLA-4 antibody and / or a bispecific anti-MUC16 / anti-CD3 antibody leads to a delay in tumor growth and progression, e.g., tumor growth may be delayed by about 3 days, more than 3 days, about 7 days, more than 7 days, more than 15 days, more than 1 month, more than 3 months, more than 6 months, more than 1 year, more than 2 years, or more than 3 years, compared to an untreated subject or a subject treated with either antibody as monotherapy. In certain embodiments, administration of an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody prevents tumor recurrence and / or increases the survival of the subject, e.g., increases the duration of survival by more than 15 days, more than 1 month, more than 3 months, more than 6 months, more than 12 months, more than 18 months, more than 24 months, more than 36 months, or more than 48 months, compared to an untreated subject or a subject administered either antibody as monotherapy. In certain embodiments, administration of the antibody combination increases progression-free survival or overall survival. In certain embodiments, administration of an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody increases the response and duration of response in a subject by, for example, more than 2%, more than 3%, more than 4%, more than 5%, more than 6%, more than 7%, more than 8%, more than 9%, more than 10%, more than 20%, more than 30%, more than 40%, or more than 50% over untreated subjects or subjects receiving either antibody as monotherapy. In certain embodiments, administration of an anti-CTLA-4 antibody and a bispecific anti-MUC16 / anti-CD3 antibody to a subject with ovarian cancer leads to the complete disappearance of all signs of tumor cells ("complete remission").In certain embodiments, administration of an anti-CTLA-4 antibody and a bispecific anti-MUC16 / anti-CD3 antibody to a subject with ovarian cancer leads to at least a 30% or greater reduction in tumor cells or tumor size ("partial response"). In certain embodiments, administration of an anti-CTLA-4 antibody and a bispecific anti-MUC16 / anti-CD3 antibody to a subject with ovarian cancer leads to complete or partial disappearance of tumor cells / lesions, including new measurable lesions. Tumor reduction can be measured by any of the methods known in the art, for example, X-ray, positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), cytology, histology, or molecular genetic analysis. In certain embodiments, administration of an anti-CTLA-4 antibody and a bispecific anti-MUC16 / anti-CD3 antibody results in a synergistic anti-tumor effect that exceeds the combined effect of the two agents when administered alone.
[0050] In certain embodiments, the administered antibody combination is safe and well tolerated by patients, with no increase in adverse side effects (increased cytokine release ("cytokine storm") or increased T cell activation) compared to patients receiving the bispecific antibody as monotherapy.
[0051] Anti-CTLA-4 antibodies and antigen-binding fragments thereof According to certain exemplary embodiments of the invention, the method comprises administering a therapeutically effective amount of an anti-CTLA-4 antibody or an antigen-binding fragment thereof. As used herein, the term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). In a typical antibody, each heavy chain comprises a heavy chain variable region (referred to herein as HCVR or VLVR). H The heavy chain constant region is made up of three domains, C H 1. C H 2, and C H Each light chain comprises a light chain variable region (referred to herein as LCVR or V L The light chain constant region comprises one domain (CL 1) is included. H Area and V L The regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), separated by regions that are relatively conserved, called framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the invention, the FRs of the anti-IL-4R antibody (or antigen-binding portion thereof) may be identical to the human germline sequence or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on the aligned analysis of two or more CDRs.
[0052] As used herein, the term "antibody" also includes antigen-binding fragments of complete antibody molecules. As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, etc., include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies may be derived from complete antibody molecules using any suitable standard method, such as, for example, proteolytic or recombinant genetic engineering techniques, involving the manipulation and expression of DNA encoding antibody variable regions and, optionally, constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated chemically or by using molecular biology techniques, for example, to place one or more variable and / or constant domains in a suitable configuration, or to introduce codons, create cysteine residues, modify, add, or delete amino acids, etc.
[0053] Non-limiting examples of antibody binding fragments include (i) Fab fragments, (ii) F(ab')2 fragments, (iii) Fd fragments, (iv) Fv fragments, (v) single chain Fv (scFv) molecules, (vi) dAb fragments, and (vii) minimal recognition units consisting of amino acid residues mimicking a hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and other engineered molecules such as shark variable IgNAR domains are also encompassed by the term "antigen-binding fragment" as used herein.
[0054] Antigen-binding fragments of antibodies typically contain at least one variable domain, which may be of any size or amino acid composition and generally contains at least one CDR adjacent to, or in frame with, one or more framework sequences. L Domain associated with V H For antigen-binding fragments containing domains, V H Domain and V L The domains may be positioned relative to each other in any suitable configuration. For example, the variable region may be a dimer and may have a V H -V H , V H -V L Or V L -V L Alternatively, the antigen-binding fragment of the antibody may comprise a monomeric V H Or V L It may contain domains.
[0055] In certain embodiments, an antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the invention include: (i) a VH -C H 1, (ii) V H -C H 2. (iii) V H -C H 3. (iv) V H -C H 1-C H 2. (v) V H -C H 1-C H 2-C H 3. (vi) V H -C H 2-C H 3. (vii) V H -C L , (viii) V L -C H 1, (ix) V L -C H 2. (x)V L -C H 3. (xi) V L -C H 1-C H 2. (xii) V L -C H 1-C H 2-C H 3. (xiii) V L -C H 2-C H 3, and (xiv) V L -C L In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Furthermore, antigen-binding fragments of antibodies of the invention may be in non-covalent association with each other and / or with one or more monomeric V H Or V LIt may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above in non-covalent association (e.g., via disulfide bonds) of the domains.
[0056] The term "antibody" as used herein also includes multispecific (e.g., bispecific) antibodies. Multispecific antibodies or antigen-binding fragments of antibodies typically comprise at least two different variable domains, each capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format can be adapted for use in connection with the antibodies or antigen-binding fragments of antibodies of the present invention using routine techniques available in the art. For example, the present invention includes methods involving the use of bispecific antibodies, in which one arm of the immunoglobulin is specific for CTLA-4 or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated to a therapeutic moiety. Exemplary bispecific formats that can be used in the context of the present invention include, but are not limited to, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadroma, knobs-into-holes, common light chains (such as common light chains with knobs-into-holes), CrossMab, CrossFab, (SEED) bodies, leucine zipper, duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab2.sup.2 bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6,1-11, and references cited therein, for a discussion of the foregoing formats). Bispecific antibodies can also be constructed using peptide / nucleic acid conjugation, for example, using unnatural amino acids with orthogonal chemical reactivity to generate site-specific antibody-oligonucleotide conjugates that then self-assemble into multimeric complexes with defined composition, valency and geometry (see, e.g., Kazane et al., J. Am. Chem. Soc. [Epub: Dec. 4, 2012]).
[0057] The antibody used in the method of the present invention may be a human antibody. The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Nevertheless, the human antibody of the present invention may include amino acid residues (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo) that are not encoded by human germline immunoglobulin sequences, for example in the CDRs, particularly CDR3. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, are grafted onto human framework sequences.
[0058] The antibody used in the method of the invention may be a recombinant human antibody. The term "recombinant human antibody", as used herein, is intended to include all human antibodies prepared, expressed, created, or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (discussed in more detail below), antibodies isolated from a recombinant, combinatorial human antibody library (discussed in more detail below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulins (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or antibodies prepared, expressed, created, or isolated by any other means involving splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or in vivo somatic mutagenesis, when using human Ig transgenic animals), thereby improving the V H Area and V L The amino acid sequence of the region is H Sequence and V LWhile the sequences are derived from and related to the sequences, they may not naturally occur in the human antibody germline repertoire in vivo.
[0059] According to certain embodiments, the antibody used in the methods of the invention specifically binds to CTLA-4. The term "specifically binds" and the like means that the antibody or antigen-binding fragment thereof forms a complex with the antigen that is relatively stable under physiological conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, as used in the context of the present invention, an antibody that "specifically binds" to CTLA-4 has a K of less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM as measured by a surface plasmon resonance assay. D However, an isolated antibody that specifically binds human CTLA-4 may have cross-reactivity to other antigens, such as CTLA-4 molecules from other (non-human) species.
[0060] According to certain exemplary embodiments of the invention, an anti-CTLA-4 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising any of the amino acid sequences of the anti-CTLA-4 antibodies described in International Patent Publication No. WO2019 / 023482. In certain exemplary embodiments, an anti-CTLA-4 antibody or antigen-binding fragment thereof that may be used in connection with the methods of the invention comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:33 and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:34. According to certain embodiments, the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), where HCDR1 comprises the amino acid sequence of SEQ ID NO: 35, HCDR2 comprises the amino acid sequence of SEQ ID NO: 36, HCDR3 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 40. In yet other embodiments, the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises a HCVR comprising SEQ ID NO: 33 and a LCVR comprising SEQ ID NO: 34. In certain embodiments, the methods of the invention comprise the use of an anti-CTLA-4 antibody, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 41. In some embodiments, the anti-CTLA-4 antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 42. An exemplary antibody comprising a HCVR comprising SEQ ID NO: 33 and a LCVR comprising SEQ ID NO: 34 is REGN4659. According to certain exemplary embodiments, the methods of the invention comprise the use of anti-CTLA-4 antibodies, or biological equivalents thereof. As used herein, the term "biological equivalent" refers to an anti-CTLA-4 antibody or CTLA-4 binding protein or fragment thereof that is a pharmaceutical equivalent or pharmaceutical substitute that exhibits a rate and / or extent of absorption that does not differ significantly from that of a sequence-defined antibody when administered under similar experimental conditions at the same molar dose, either in a single dose or in multiple doses.In the context of the present invention, the term refers to an antigen-binding protein that binds to CTLA-4 without any clinically meaningful differences in safety, purity and / or potency.
[0061] The anti-CTLA-4 antibodies used in connection with the methods of the invention may have pH-dependent binding properties. For example, the anti-CTLA-4 antibodies for use in the methods of the invention may exhibit reduced binding to CTLA-4 at acidic pH compared to neutral pH. Alternatively, the anti-CTLA-4 antibodies of the invention may exhibit enhanced binding to their antigen at acidic pH compared to neutral pH. The term "acidic pH" includes pH values less than about 6.2, such as about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0 or less. As used herein, the term "neutral pH" refers to a pH of about 7.0 to about 7.4. The expression "neutral pH" includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
[0062] In certain instances, "reduced binding to CTLA-4 at acidic pH compared to neutral pH" refers to the K value of antibody binding to CTLA-4 at acidic pH relative to the K value of antibody binding to CTLA-4 at neutral pH. D For example, an antibody or antigen-binding fragment thereof may be used that has an acidic / neutral K of about 3.0 or greater. D For purposes of the present invention, an antibody or antigen-binding fragment of the present invention may be considered to exhibit "reduced binding to CTLA-4 at acidic pH compared to neutral pH." In certain exemplary embodiments, an antibody or antigen-binding fragment of the present invention may exhibit an acidic / neutral K DThe ratio can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0, or more.
[0063] Antibodies with pH-dependent binding properties can be obtained, for example, by screening a population of antibodies for reduced (or increased) binding to a particular antigen at acidic pH compared to neutral pH. In addition, modification of the antigen-binding domain in amino acid concentration can produce antibodies with pH-dependent properties. For example, by replacing one or more amino acids in the antigen-binding domain (e.g., in the CDR) with histidine residues, an antibody can be obtained with reduced antigen binding at acidic pH compared to neutral pH. As used herein, the term "acidic pH" refers to a pH of 6.0 or less.
[0064] Bispecific anti-MUC16 / anti-CD3 antibody According to certain exemplary embodiments of the invention, the methods comprise administering a therapeutically effective amount of a bispecific antibody that specifically binds CD3 and MUC16. Such molecules may be referred to herein, for example, as "anti-MUC16 / anti-CD3," or "anti-MUC16xCD3," or "MUC16xCD3" bispecific molecules, or other similar terms.
[0065] As used herein, the expression "bispecific antibody" refers to an immunoglobulin protein comprising at least a first antigen-binding domain and a second antigen-binding domain. In the context of the present invention, the first antigen-binding domain specifically binds to a first antigen (e.g., MUC16) and the second antigen-binding domain specifically binds to a second distinct antigen (e.g., CD3). Each antigen-binding domain of a bispecific antibody comprises a heavy chain variable domain (HCVR) and a light chain variable domain (LCVR), each comprising three CDRs. In the context of a bispecific antibody, the CDRs of the first antigen-binding domain may be designated with the prefix "A" and the CDRs of the second antigen-binding domain may be designated with the prefix "B". Thus, the CDRs of the first antigen-binding domain may be referred to herein as A-HCDR1, A-HCDR2, and A-HCDR3, and the CDRs of the second antigen-binding domain may be referred to herein as B-HCDR1, B-HCDR2, and B-HCDR3.
[0066] The first antigen-binding domain and the second antigen-binding domain are each connected to a separate multimerizing domain. As used herein, a "multimerizing domain" is any macromolecule, protein, polypeptide, peptide, or amino acid that has the ability to associate with a second multimerizing domain of the same or similar structure or composition. In the context of the present invention, a multimerizing component is a multimerizing component having a structure such as (C H2 -C H3 The Fc portion of an immunoglobulin (including its Fc domain), such as the Fc domain of an IgG selected from the isotypes IgG1, IgG2, IgG3, and IgG4, as well as any allotype within each isotype group.
[0067] A bispecific antigen-binding molecule of the invention typically comprises two multimerization domains, e.g., two Fc domains, each of which is part of an individual, separate antibody heavy chain. The first and second multimerization domains may be of the same IgG isotype, e.g., IgG1 / IgG1, IgG2 / IgG2, IgG4 / IgG4, etc. Alternatively, the first and second multimerization domains may be of different IgG isotypes, e.g., IgG1 / IgG2, IgG1 / IgG4, IgG2 / IgG4, etc.
[0068] Any bispecific antibody format or technique may be used to generate the bispecific antigen-binding molecules of the invention. For example, an antibody or fragment thereof having a first antigen-binding specificity can be operatively linked (e.g., by chemical conjugation, genetic fusion, or non-covalent association, or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment having a second binding specificity, to generate a bispecific antigen-binding molecule. Specific exemplary bispecific formats that may be used in connection with the present invention include, but are not limited to, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable region (DVD)-Ig, quadroma, knob-into-hole, common light chain (e.g., common light chain with knob-into-hole), CrossMab, CrossFab, (SEED) body, leucine zipper, duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab. 2 and bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-11, and references cited therein for a discussion of the aforementioned formats).
[0069] In the context of the bispecific antigen-binding molecules of the invention, the Fc domain may contain one or more amino acid changes (e.g., insertions, deletions, or substitutions) compared to a naturally occurring version of the wild-type Fc domain. For example, the invention includes bispecific antigen-binding molecules that contain one or more modifications in the Fc domain that result in a modified Fc domain with an altered binding interaction (e.g., enhanced or reduced) between Fc and FcRn. In one embodiment, the bispecific antigen-binding molecule comprises a C H2 Area or C H3 The FcRn domain may comprise modifications in regions that increase the affinity of the Fc domain for FcRn in acidic environments (e.g., in endosomes at a pH ranging from about 5.5 to about 6.0). Non-limiting examples of such Fc modifications are disclosed in U.S. Patent Publication No. 2015 / 0266966, which is incorporated herein in its entirety.
[0070] The present invention also relates to a first C H 3 domain and second Ig C H The bispecific antigen-binding molecule comprises a first and a second IgC domain. H In one embodiment, the first Ig C domain is a 2-amino acid ... H The 3 domain binds to protein A and the second Ig C H The third domain contains a mutation that reduces or eliminates Protein A binding, for example the H95R modification (according to the IMGT exon numbering; H435R according to the EU numbering). H 3 may further include a Y96F modification (Y436F according to IMGT and according to the EU). See, e.g., U.S. Patent No. 8,586,713. HFurther modifications that may be found in 3 include: D16E, L18M, N44S, K52N, V57M, and V82I for IgG1 antibodies (D356E, L358M, N384S, K392N, V397M, and V422I in EU by IMGT), N44S, K52N, and V82I for IgG2 antibodies (N384S, K392N, and V422I in IMGT, EU), and Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I for IgG4 antibodies (Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I in EU by IMGT).
[0071] In certain embodiments, the Fc domain may be a chimera that combines Fc sequences from two or more immunoglobulin isotypes. For example, a chimeric Fc domain may be a chimeric Fc domain that combines Fc sequences from human IgG1, human IgG2, or human IgG4 C. H C derived from 2 regions H 2 sequences, and C derived from human IgG1, human IgG2, or human IgG4. H The chimeric Fc domain may comprise some or all of the three sequences. The chimeric Fc domain may also contain a chimeric hinge region. For example, the chimeric hinge may comprise an "upper hinge" sequence derived from a human IgG1, human IgG2, or human IgG4 hinge region combined with a "lower hinge" sequence derived from a human IgG1, human IgG2, or human IgG4 hinge region. A particular example of a chimeric Fc domain that may be included in any of the antigen binding molecules described herein is, from the N-terminus to the C-terminus, [IgG4 C H Another example of a chimeric Fc domain that may be included in any of the antigen-binding molecules described herein comprises, from the N-terminus to the C-terminus, [IgG1 C HIgG1 CH3]-[IgG1 upper hinge]-[IgG2 lower hinge]-[IgG4 CH2]-[IgG1 CH3]. These and other examples of chimeric Fc domains that may be included in any of the antigen binding molecules of the invention are described in U.S. Patent Publication No. 2014 / 0243504, which is incorporated herein in its entirety. Chimeric Fc domains having these general structural arrangements, and variants thereof, may have altered Fc receptor binding and therefore affect Fc effector function.
[0072] According to certain exemplary embodiments of the invention, the bispecific anti-MUC16 / anti-CD3 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (A-HCVR and B-HCVR), a light chain variable region (A-LCVR and B-LCVR), and / or a complementarity determining region (CDR) comprising any of the amino acid sequences of the bispecific anti-MUC16 / anti-CD3 antibodies described in U.S. Patent Publication No. 2018 / 0112001. In certain exemplary embodiments, a bispecific anti-MUC16 / anti-CD3 antibody or antigen-binding fragment thereof that may be used in connection with the methods of the invention comprises (a) a first antigen-binding arm comprising heavy chain complementarity determining regions (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO:1 and light chain complementarity determining regions (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO:2, and (b) a second antigen-binding arm comprising heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a HCVR (B-HCVR) comprising the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, and light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a LCVR (B-LCVR) comprising the amino acid sequence of SEQ ID NO:2. According to certain embodiments, A-HCDR1 comprises the amino acid sequence of SEQ ID NO:8, A-HCDR2 comprises the amino acid sequence of SEQ ID NO:9, A-HCDR3 comprises the amino acid sequence of SEQ ID NO:10, A-LCDR1 comprises the amino acid sequence of SEQ ID NO:11, A-LCDR2 comprises the amino acid sequence of SEQ ID NO:12, and A-LCDR3 comprises the amino acid sequence of SEQ ID NO:13, B-HCDR1 comprises the amino acid sequence of SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26, B-HCDR2 comprises the amino acid sequence of SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, or SEQ ID NO:27, and B-HCDR3 comprises the amino acid sequence of SEQ ID NO:16, SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:25, or SEQ ID NO:28, B-LCDR1 comprises the amino acid sequence of SEQ ID NO:11, B-LCDR2 comprises the amino acid sequence of SEQ ID NO:12, and B-LCDR3 comprises the amino acid sequence of SEQ ID NO:13.In yet other embodiments, the bispecific anti-MUC16 / anti-CD3 antibody, or antigen-binding fragment thereof, comprises (a) a first antigen-binding arm comprising a HCVR comprising SEQ ID NO:1 (A-HCVR) and a LCVR comprising SEQ ID NO:2 (A-LCVR), and (b) a second antigen-binding arm comprising a HCVR comprising SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7 (B-HCVR) and a LCVR comprising SEQ ID NO:2 (B-LCVR). In certain exemplary embodiments, the bispecific anti-CD3 x MUC16 antibody comprises a MUC16-binding arm comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:30, and a CD3-binding arm comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:31 and a light chain comprising the amino acid sequence of SEQ ID NO:30. In certain exemplary embodiments, the bispecific anti-CD3xMUC16 antibody comprises a MUC16-binding arm comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:30, and a CD3-binding arm comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:32 and a light chain comprising the amino acid sequence of SEQ ID NO:30.
[0073] Other bispecific anti-MUC16 / anti-CD3 antibodies that may be used in connection with the methods of the invention include, for example, any of the antibodies described in International Patent Publication No. WO2018 / 067331.
[0074] Combination therapy According to certain embodiments, the methods of the invention include administering a bispecific anti-MUC16 / anti-CD3 antibody to a subject in combination with an anti-CTLA-4 antibody. In certain embodiments, the methods of the invention include administering the antibodies for additive or synergistic activity to treat cancer, preferably ovarian cancer. As used herein, the term "in combination with" means that the anti-MUC16 / anti-CD3 bispecific antibody is administered before, after, or simultaneously with the anti-CTLA-4 antibody. The term "in combination with" also includes sequential or simultaneous administration of the anti-CTLA-4 antibody and the bispecific anti-MUC16 / anti-CD3 antibody. For example, when administered "prior to" the bispecific anti-MUC16 / anti-CD3 antibody, the anti-CTLA-4 antibody may be administered more than 150 hours, about 150 hours, about 100 hours, about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, about 15 minutes, or about 10 minutes before administration of the bispecific anti-MUC16 / anti-CD3 antibody. When administered "after" the bispecific anti-MUC16 / anti-CD3 antibody, the anti-CTLA-4 antibody may be administered about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, or more than 72 hours after administration of the bispecific anti-MUC16 / anti-CD3 antibody. "Concurrent administration" with the bispecific anti-MUC16 / anti-CD3 antibody means that the anti-CTLA-4 antibody is administered to the subject in a separate dosage form within less than 5 minutes of (before, after, or simultaneously with) administration of the bispecific anti-MUC16 / anti-CD3 antibody, or is administered to the subject as a single, combined dosage formulation including both the anti-CTLA-4 antibody and the bispecific anti-MUC16 / anti-CD3 antibody.
[0075] In certain embodiments, the method of the present invention includes administration of a third therapeutic agent, and the third therapeutic agent is an anti-cancer agent. As used herein, "anti-cancer agent" refers to any agent useful for treating cancer, including, but not limited to, cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotics, procarbazine, hydroxyurea, asparaginase, corticosteroids, mitotane (O,P'-(DDD)), biologics (e.g., antibodies and interferons), and radioactive agents. As used herein, "cytotoxins or cytotoxic agents" also refers to chemotherapeutic agents and refers to any agent that is harmful to cells. Examples include Taxol® (paclitaxel), temozolamide, cytochalasin B, gramicidin D, ethidium bromide, emetine, cisplatin, mitomycin, etoposide, tenoposide, vincristine, vinbiastine, coichicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydroterosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin, as well as analogs or homologs thereof.
[0076] In certain embodiments, the methods of the invention include treatment with a combination of radiation, surgery, a cancer vaccine, a PD-1 inhibitor (e.g., an anti-PD-1 antibody), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody), a LAG-3 inhibitor, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, an antagonist of another T cell co-inhibitor or ligand (e.g., an antibody against CD-28, 2B4, LY108, LAIR1, ICOS, CD160, or VISTA), an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept or U.S. Pat. No. 5,313,636), ... "VEGF-Trap," such as other VEGF inhibitor fusion proteins described in US Pat. No. 7,087,411, or anti-VEGF antibodies or antigen-binding fragments thereof (e.g., bevacizumab, or ranibizumab) or small molecule kinase inhibitors of the VEGF receptor (e.g., sunitinib, sorafenib, or pazopanib)], Ang2 inhibitors (e.g., nesvacumab), transforming growth factor beta (TGF.beta.) inhibitors, epidermal growth factor receptor (EGFR) inhibitors (e.g., erlotinib, cetuximab), agonists for costimulatory receptors (e.g., agonists for glucocorticoid-inducible TNFR-associated protein), antibodies against tumor-specific antigens (e.g., CA9, CA125, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin-1, MART-1, and CA19-9), vaccines (e.g., Bacillus Calmette-Guerin, cancer vaccines), adjuvants to increase antigen presentation (e.g., granulocyte-macrophage colony-stimulating factor), cytotoxins, chemotherapeutic agents (e.g., dacarbazine, temozolomide, cyclophosphamide, docetaxel, doxorubicin, daunorubicin, cisplatin, carboplatin, gemcitabine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, and vincristine), radiation therapy, IL-6R inhibitors (e.g., sarilumab), IL-4R inhibitors (e.g., dupilumab), IL-10 inhibitors, cytokines such as IL-2, IL-7, IL-21, and IL-15, antibody drug conjugates (ADCs) (e.g., anti-CD19-DM4 ADC, and anti-DS6-DM4 ADC). ADC), chimeric antigen receptor T cells (e.g., CD19-targeted T cells), anti-inflammatory drugs (e.g., corticosteroids and nonsteroidal anti-inflammatory drugs), and nutritional supplements such as antioxidants.
[0077] In certain embodiments, the methods provided herein comprise administering an anti-CTLA-4 antibody and a bispecific anti-MUC16 / anti-CD3 antibody in combination with radiation therapy / chemotherapy to generate a long-lasting anti-tumor response and / or enhance survival of patients with cancer.
[0078] In some embodiments, the methods of the invention include administering radiation therapy before, simultaneously with, or after administering anti-CTLA-4 antibodies and bispecific anti-MUC16 / anti-CD3 antibodies to a cancer patient. For example, radiation therapy may be administered in one or more doses to a tumor lesion after administration of one or more doses of antibodies. In some embodiments, radiation therapy may be administered locally to a tumor lesion after systemic administration of anti-CTLA-4 antibodies and / or bispecific anti-MUC16 / anti-CD3 antibodies to increase the local immunogenicity of the patient's tumor (adjuvanting radiation) and / or kill tumor cells (ablative radiation). In certain embodiments, the antibodies may be administered in combination with radiation therapy and a chemotherapeutic agent (e.g., carboplatin and / or paclitaxel) or a VEGF antagonist (e.g., aflibercept).
[0079] Pharmaceutical Compositions and Administration The present invention includes methods comprising administering to a subject an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody, the antibodies being contained within a separate or combined (single) pharmaceutical composition. The pharmaceutical compositions of the present invention may be formulated with suitable carriers, excipients, and other agents that provide suitable transport, delivery, tolerance, and the like. Numerous suitable formulations can be found in a formulary known to every pharmacist: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.
[0080] Various delivery systems are known and can be used to administer the pharmaceutical composition of the present invention. For example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis, etc. (see, for example, Wu et al., 1987, J.Biol.Chem.262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents.
[0081] The pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously using a standard needle and syringe. In addition, for subcutaneous delivery, a pen delivery device is easily applied in the delivery of the pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge containing the pharmaceutical composition. Once all of the pharmaceutical composition inside the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device is sold in a pre-filled state with the pharmaceutical composition held in a reservoir inside the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.
[0082] In certain circumstances, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used. In another embodiment, a polymeric material can be used. See Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla. In yet another embodiment, the controlled release system can be placed in the vicinity of the target of the composition, thus requiring only a fraction of the systemic dose (see, for example, Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249: 1527-1533.
[0083] The injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal, and intramuscular injections, drip infusions, and the like. These injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared by dissolving, suspending, or emulsifying the above-mentioned antibody or its salt in a sterile aqueous or oily medium conventionally used for injections. The aqueous medium for injection may be, for example, physiological saline, an isotonic solution containing glucose, and other auxiliary agents, which may be used in combination with a suitable solubilizing agent such as alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)]. As the oily medium, for example, sesame oil, soybean oil, and the like may be employed, which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, and the like. The injection solution thus prepared is preferably filled into a suitable ampoule.
[0084] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared in dosage forms with unit doses suitable for the dosage of the active ingredient.Such dosage forms in unit doses include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
[0085] Dosing regimen The invention includes methods comprising administering to a subject an anti-CTLA-4 antibody at a dosing frequency of about 4 times per week, twice per week, once per week, once per 2 weeks, once per 3 weeks, once per 4 weeks, once per 5 weeks, once per 6 weeks, once per 8 weeks, once per 12 weeks, or less frequently, so long as a therapeutic response is achieved. In certain embodiments, the invention includes methods comprising administering to a subject a bispecific anti-MUC16 / anti-CD3 antibody at a dosing frequency of about 4 times per week, twice per week, once per week, once per 2 weeks, once per 3 weeks, once per 4 weeks, once per 5 weeks, once per 6 weeks, once per 8 weeks, once per 12 weeks, or less frequently, so long as a therapeutic response is achieved. In certain embodiments, the methods comprise administration of an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody at a dosing frequency of about 4 times per week, twice per week, once per week, once per 2 weeks, once per 3 weeks, once per 4 weeks, once per 5 weeks, once per 6 weeks, once per 8 weeks, once per 9 weeks, once per 12 weeks, or less frequently, so long as a therapeutic response is achieved.
[0086] According to certain embodiments of the invention, multiple doses of anti-CTLA-4 antibody in combination with bispecific anti-MUC16 / anti-CD3 antibody may be administered to a subject over a defined time course. The method according to this aspect of the invention comprises sequentially administering to a subject one or more doses of anti-CTLA-4 antibody in combination with one or more doses of bispecific anti-MUC16 / anti-CD3 antibody. As used herein, "sequentially administering" means that each dose of antibody is administered to a subject at different times, e.g., on different days separated by a predefined interval (e.g., hours, days, weeks, or months). The invention includes methods comprising sequentially administering to a patient a single initial dose of anti-CTLA-4 antibody, followed by one or more secondary doses of anti-CTLA-4 antibody, and optionally one or more tertiary doses of anti-CTLA-4 antibody. In certain embodiments, the methods further comprise sequentially administering to the patient a single initial dose of the bispecific anti-MUC16 / anti-CD3 antibody, followed by one or more secondary doses of the bispecific antibody, optionally followed by one or more tertiary doses of the bispecific anti-MUC16 / anti-CD3 antibody.
[0087] According to certain embodiments of the invention, multiple doses of the anti-CTLA-4 antibody and the bispecific anti-MUC16 / anti-CD3 antibody may be administered to the subject over a defined time course. The method according to this aspect of the invention comprises sequentially administering multiple doses of the anti-CTLA-4 antibody and the bispecific anti-MUC16 / anti-CD3 antibody to the subject. As used herein, "sequentially administering" means that each dose of the anti-CTLA-4 antibody in combination with the bispecific antibody is administered to the subject at different times, such as on different days separated by a predefined interval (e.g., hours, days, weeks or months).
[0088] The terms "initial dose", "secondary dose" and "tertiary dose" refer to the temporal order of administration. Thus, an "initial dose" is a dose administered at the beginning of a treatment regimen (also referred to as a "baseline dose"), a "secondary dose" is a dose administered after the initial dose, and a "tertiary dose" is a dose administered after the secondary dose. The initial dose, secondary dose, and tertiary dose may all contain the same amount of antibody (anti-CTLA-4 antibody or bispecific antibody). However, in certain embodiments, the amounts contained in the initial dose, secondary dose, and / or tertiary dose differ from each other (e.g., adjusted up or down) during the course of treatment. In certain embodiments, one or more doses (e.g., 1, 2, 3, 4, or 5) are administered as a "loading dose" at the beginning of a treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered on a less frequent basis. For example, an anti-CTLA-4 antibody may be administered to a patient with ovarian cancer at a loading dose of about 1-3 mg / kg, followed by one or more maintenance doses of about 0.1-20 mg / kg of the patient's body weight.
[0089] In an exemplary embodiment of the invention, each secondary dose and / or tertiary dose is administered ½ to 14 weeks after the immediately preceding dose (e.g., ½ week, 1 week, 1 ½ weeks, 2 weeks, 2 ½ weeks, 3 weeks, 3 ½ weeks, 4 weeks, 4 ½ weeks, 5 weeks, 5 ½ weeks, 6 weeks, 6 ½ weeks, 7 weeks, 7 ½ weeks, 8 weeks, 8 ½ weeks, 9 weeks, 9 ½ weeks, 10 weeks, 10 ½ weeks, 11 weeks, 11 ½ weeks, 12 weeks, 12 ½ weeks, 13 weeks, 13 ½ weeks, 14 weeks, 14 ½ weeks, or more). As used herein, the phrase "the immediately preceding dose" refers to a dose of an anti-CTLA-4 antibody (and / or a bispecific anti-MUC16 / anti-CD3 antibody) in a multiple dose series that is administered to a patient prior to administration of the immediately next dose in the series, with no intervening doses.
[0090] Methods according to this aspect of the invention may include administering any number of secondary and / or tertiary doses of an anti-CTLA-4 antibody (and / or a bispecific anti-MUC16 / anti-CD3 antibody) to the patient. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Similarly, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.
[0091] In embodiments including multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1-2 weeks after the immediately preceding administration. Similarly, in embodiments including multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2-4 weeks after the immediately preceding administration. Alternatively, the frequency with which the secondary and / or tertiary doses are administered to the patient may vary over the course of the treatment regimen. The frequency of administration may also be adjusted by the physician during the course of treatment depending on the needs of the individual patient after clinical testing.
[0092] In certain embodiments, one or more doses of anti-CTLA-4 antibody and / or bispecific anti-MUC16 / anti-CD3 antibody are administered more frequently (twice per week, once per week, or once every two weeks) at the start of a treatment regimen as an "induction dose," followed by subsequent doses ("consolidation doses" or "maintenance doses") administered less frequently (e.g., once every 4-12 weeks).
[0093] The present invention includes methods comprising sequentially administering to a patient an anti-CTLA-4 antibody in combination with a bispecific anti-MUC16 / anti-CD3 antibody to treat ovarian cancer (e.g., serous cancer). In some embodiments, the methods comprise administering one or more doses of an anti-CTLA-4 antibody, followed by one or more doses of a bispecific anti-MUC16 / anti-CD3 antibody. In certain embodiments, the methods comprise administering a single dose of an anti-CTLA-4 antibody, followed by one or more doses of a bispecific anti-MUC16 / anti-CD3 antibody. In some embodiments, one or more doses of an anti-CTLA-4 antibody at about 0.1 mg / kg to about 20 mg / kg can be administered, followed by one or more doses of a bispecific antibody at about 0.1 mg / kg to about 20 mg / kg to inhibit tumor growth and / or prevent tumor recurrence in a subject with ovarian cancer. In some embodiments, administration of one or more doses of an anti-CTLA-4 antibody followed by administration of one or more doses of a bispecific antibody results in an increased anti-tumor effect (e.g., greater inhibition of tumor growth, improved prevention of tumor recurrence compared to untreated subjects or subjects administered either antibody as monotherapy). Alternative embodiments of the invention relate to the co-administration of an anti-CTLA-4 antibody and a bispecific antibody administered in separate doses at a similar or different frequency compared to the anti-CTLA-4 antibody. In some embodiments, the bispecific antibody is administered before, after, or simultaneously with the anti-CTLA-4 antibody. In certain embodiments, the bispecific antibody is administered in a single dose formulation with the anti-CTLA-4 antibody.
[0094] Dosage The amount of anti-CTLA-4 antibody and / or bispecific anti-MUC16 / anti-CD3 antibody administered to a subject according to the methods of the invention is generally a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" refers to an amount of antibody (anti-CTLA-4 antibody or bispecific anti-MUC16 / anti-CD3 antibody) that results in one or more of the following, compared to untreated subjects or subjects administered either antibody as monotherapy: (a) a reduction in the severity of cancer (e.g., ovarian cancer) or the duration of cancer symptoms; (b) inhibition of tumor growth or an increase in tumor necrosis, tumor shrinkage and / or tumor disappearance; (c) a delay in tumor growth and development; (d) inhibition or a delay or cessation of tumor metastasis; (e) prevention of recurrence of tumor growth; (f) an increase in survival of subjects with cancer (e.g., ovarian cancer); and / or (g) a reduction in the use or need for conventional anti-cancer therapies (e.g., a reduction or elimination of the use of chemotherapeutic or cytotoxic agents).
[0095] In the case of an anti-CTLA-4 antibody (or antigen-binding fragment), a therapeutically effective amount is about 0.05 mg to about 1500 mg, for example, about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg The amount of the anti-CTLA-4 antibody may be about 70 mg, about 180 mg, about 190 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, or about 1500 mg. In some cases, the therapeutically effective amount of the anti-CTLA-4 antibody (or antigen-binding fragment) may be about 0.5 mg / kg to about 2.5 mg / kg, or about 20 mg to about 250 mg.
[0096] In the case of a bispecific anti-MUC16 / anti-CD3 antibody, a therapeutically effective amount can be from about 10 mg to 1500 mg, e.g., about 10 mg, about 20 mg, about 50 mg, about 70 mg, about 100 mg, about 120 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, or about 1500 mg of a bispecific anti-MUC16 / anti-CD3 antibody. In some cases, a therapeutically effective amount of an anti-MUC16×CD3 bispecific antibody can be from about 30 mg to about 900 mg.
[0097] The amount of either the anti-CTLA-4 antibody or the bispecific anti-MUC16 / anti-CD3 antibody contained in an individual dose may be expressed in milligrams per kilogram (i.e., mg / kg) of the subject's body weight. In certain embodiments, either the anti-CTLA-4 antibody or the bispecific anti-MUC16 / anti-CD3 antibody used in the methods of the invention may be administered to the subject at a dose of about 0.0001 to about 100 mg / kg of the subject's body weight. For example, the anti-CTLA-4 antibody may be administered at a dose of about 0.1 mg / kg to about 20 mg / kg of the subject's body weight. The bispecific anti-MUC16 / anti-CD3 antibody may be administered at a dose of about 0.1 mg / kg to about 20 mg / kg of the subject's body weight.
[0098] A summary of the sequences referred to herein and their corresponding SEQ ID NOs is provided in Table 1 below. [Table 1] EXAMPLES
[0099] The following examples are provided to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventor regards as his invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is degrees Celsius, and pressure is at or near atmospheric pressure.
[0100] Example 1: Generation of a bispecific antibody that binds MUC16 and CD3 The present invention also provides bispecific antigen-binding molecules that bind CD3 and MUC16, such bispecific antigen-binding molecules are also referred to herein as "anti-MUC16 / anti-CD3 or anti-MUC16xCD3 bispecific molecules." The anti-MUC16 portion of the anti-MUC16 / anti-CD3 bispecific molecule is designed to target tumor cells that express MUC16 (also known as CA-125), and the anti-CD3 portion of the bispecific molecule is designed to activate T cells. The simultaneous binding of MUC16 on tumor cells and CD3 on T cells promotes direct killing (cytolysis) of the targeted tumor cells by the activated T cells.
[0101] Bispecific antibodies comprising an anti-MUC16 specific binding domain and an anti-CD3 specific binding domain were constructed using standard methodology, with the anti-MUC16 antigen binding domain and the anti-CD3 antigen binding domain each comprising a distinct HCVR paired with a common LCVR. In the exemplified bispecific antibody, the molecule was constructed utilizing a heavy chain from an anti-CD3 antibody, a heavy chain from an anti-MUC16 antibody, and a common light chain from an anti-MUC16 antibody. In other examples, bispecific antibodies may be constructed utilizing a heavy chain from an anti-CD3 antibody, a heavy chain from an anti-MUC16 antibody, and a light chain from an anti-CD3 antibody, or an antibody light chain that is known to be promiscuous or that is known to pair effectively with a variety of heavy chain arms.
[0102] Exemplary bispecific antibodies were generated with an IgG1 Fc domain (BSMUC16 / CD3-001, -002, -003, and -004) or an engineered (chimeric) IgG4 Fc domain (BSMUC16 / CD3-005) as described in U.S. Patent Application Publication No. US2014 / 0243504A1, published August 28, 2014.
[0103] An overview of the antigen-binding domain components of the various anti-MUC16xCD3 bispecific antibodies constructed is provided in Table 2. [Table 2]
[0104] Example 2: CTLA-4 blockade enhances the anti-tumor activity of an anti-MUC16 x CD3 bispecific antibody in a syngeneic tumor model The in vivo efficacy of anti-MUC16 / anti-CD3 (BSMUC16 / CD3-001, also referred to herein as REGN4018) bispecific antibody in combination with CTLA-4 blockade was evaluated in syngeneic tumor models in three experiments.
[0105] In these experiments, immunocompetent mice were engineered to replace the mouse CD3 gene with human CD3 and part of the mouse MUC16 gene with human sequences, resulting in mice whose T cells express human CD3 and a chimeric MUC16 molecule that contains the portion of human MUC16 that is bound by the REGN4018 bispecific antibody.
[0106] All three experiments used the ID8-VEGF cell line (a mouse ovarian carcinoma) engineered to express a portion of human MUC16. The anti-CTLA-4 antibody used in these experiments was derived from a commercially available mouse antibody (clone 9D9, Bio X Cell) in which the mIgG2b had been replaced with the mIgG2a isotype. The anti-CTLA-4 antibody with the mIgG2a isotype and the mIgG2a isotype control were generated at Regeneron (Tarrytown, NY).
[0107] A. Experiment 1 In the first experiment, mice were injected with ID8-VEGF / huMUC16 cells at 10 7 Mice were randomized on day 4, with the mean tumor volume in each group being 60 mm 3 Mice were treated with REGN4018 (5 mg / kg, IP) in combination with anti-CTLA-4 antibody (5 mg / kg, IP) or mIgG2a isotype control (5 mg / kg, IP) or CD3 binding control (5 mg / kg, IP) starting on day 4 after tumor implantation and then on days 6, 10, 14, and 17.
[0108] The data shown in Table 3 represent the mean tumor volume assessed 39 days after tumor implantation, the last day all mice were alive. At subsequent time points, mice with tumor burdens exceeding the maximum allowed by the IACUC were sacrificed. Statistical significance was determined by one-way analysis of variance (non-parametric) with Kruskal-Wallis comparison test. Treatment with the combination of REGN4018 and anti-CTLA-4 antibody resulted in significant inhibition of tumor growth compared to the combination of CD3 binding control and isotype control (p<0.01), whereas treatment with REGN4018 monotherapy or anti-CTLA-4 antibody monotherapy did not result in tumor growth inhibition. By day 61, the final time point of the experiment, there were three tumor-free mice in the combination group of REGN4018 and anti-CTLA-4 antibody. [Table 3]
[0109] B. Experiment 2 In a second experiment, the effect of REGN4018 antibody in combination with low doses (2.5 mg / kg or 0.5 mg / kg) of anti-CTLA-4 antibody on tumor growth was tested in the same syngeneic tumor model. Mice were inoculated with ID8-VEGF / huMUC16 cells at 10 7 The subjects were randomized on day 5 and the mean tumor volume in each group was 80 mm 3Mice were treated with REGN4018 (5 mg / kg, IP) or CD3 binding control (5 mg / kg, IP) in combination with anti-CTLA-4 antibody (2.5 mg / kg or 0.5 mg / kg IP) or isotype control (2.5 mg / kg, IP) starting on day 5 after tumor implantation and then on days 7, 11, 15, and 18.
[0110] The mean tumor volumes for each group on day 34, the final time point of tumor measurements, are shown in Table 4. Statistical significance was determined by one-way analysis of variance (non-parametric) with Kruskal-Wallis comparison test. Treatment with 5 mg / kg REGN4018 in combination with either 2.5 mg / kg or 0.5 mg / kg anti-CTLA-4 antibody resulted in significant inhibition of tumor growth compared to the CD3 binding control and isotype control combinations (p<0.001), whereas treatment with REGN4018 monotherapy or anti-CTLA-4 antibody monotherapy did not result in tumor growth inhibition. [Table 4]
[0111] C. Experiment 3 In the third experiment in the ascites tumor model, mice were inoculated with 5 × 10 ID8-VEGF / huMUC16 cells. 5Mice were injected intraperitoneally (IP) at day 0 with 100 mg / mL of 10 ... As shown in Table 5, treatment with the combination of REGN4018 and anti-CTLA-4 antibody extended the median survival to 50 days compared to the median survival of 34 days seen in the groups receiving the CD3 binding control and isotype control combinations (p<0.001, Mantel-Cox method), demonstrating significant anti-tumor efficacy of the combination therapy with REGN4018 and anti-CTLA4 antibody.
[0112] To ensure that the increase in median survival time of mice in the group receiving the combination of REGN4018 and anti-CTLA4 was due to the increased efficacy of the combination therapy itself and not due to the toxicity of the combination, a control experiment was performed. In this control experiment, naive non-tumor-bearing mice were treated with REGN4018 (5 mg / kg, IP) and anti-CTLA-4 antibody (5 mg / kg, IP) using the same treatment schedule described above. The results showed that the combination therapy did not induce weight loss in naive non-tumor-bearing mice (data not shown). This confirmed that the weight loss in tumor-bearing mice was the result of the increased efficacy of the combination therapy that led to a decrease in tumor weight, and not due to the toxicity of the combination therapy. [Table 5]
[0113] Example 3: Evaluation of serum cytokine induction in tumor-bearing mice Because cytokine release syndrome is a frequent severe side effect of CD3 bispecific or anti-CTLA-4 antibody treatment in humans, T cell activation was assessed by measuring serum cytokines following treatment with REGN4018 in combination with anti-CTLA-4 antibodies in genetically humanized MUC16 / CD3 naive non-tumor-bearing mice. Serum samples were collected 4 hours after treatment with a single dose of REGN4018 (5 mg / kg, IP) or CD3 binding control (5 mg / kg, IP) in combination with anti-CTLA-4 antibodies (5 mg / kg, IP) or isotype control (5 mg / kg, IP). Serum cytokine levels of interleukin-2 (IL-2), IL-6, interferon gamma (IFNγ), IL-10, IL-12p70, CXC motif cytokine ligand 1 (CXCL1), tumor necrosis factor alpha (TNFα), IL-5, and IL-1 were analyzed using a V-PLEX ProInflammatory Panel I Human Kit (Meso Scale Discovery, Rockville, MA) according to the manufacturer's instructions. β cytokines were measured in two separate studies with five mice per group.
[0114] The combination of a single dose of REGN4018 (5 mg / kg) and anti-CTLA-4 antibody (5 mg / kg), as well as REGN4018 (5 mg / kg) or anti-CTLA-4 antibody (5 mg / kg) monotherapy, did not result in a significant increase in serum cytokines in humanized MUC16 / CD3 naive mice compared to controls at 4 hours post-dose (data not shown).
[0115] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to be within the scope of the appended claims. ******* [Table 6]
Claims
1. 1. A method of treating or inhibiting the growth of a MUC16-expressing tumor, comprising administering to a subject in need thereof (a) a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3, and (b) a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
2. 2. The method of claim 1, wherein the MUC16-expressing tumor is selected from ovarian cancer, ovarian serous carcinoma, breast cancer, invasive lobular breast cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, bladder cancer, or non-small cell lung cancer.
3. The method of claim 1 or 2, wherein the MUC16-expressing tumor is ovarian cancer or ovarian serous carcinoma.
4. The method of any one of claims 1 to 3, wherein the subject is refractory to or has responded inadequately to or has subsequently relapsed from a previous therapy.
5. The method of any one of claims 1 to 4, wherein the bispecific antibody is administered at a dose of 0.1 mg / kg to 20 mg / kg of the subject's body weight.
6. The method of any one of claims 1 to 5, wherein the anti-CTLA4 antibody or antigen-binding fragment thereof is administered at a dose of 0.1 mg / kg to 20 mg / kg of the subject's body weight.
7. The method of any one of claims 1 to 6, wherein the anti-CTLA4 antibody or antigen-binding fragment thereof and / or the bispecific antibody is administered at a dose of 10 mg to 1500 mg.
8. The method of any one of claims 1 to 7, wherein one or more doses of the bispecific antibody are administered together with one or more doses of the anti-CTLA4 antibody or antigen-binding fragment thereof.
9. 9. The method of claim 8, wherein the subsequent dose of the anti-CTLA4 antibody or antigen-binding fragment thereof and / or the bispecific antibody is administered 0.5 to 12 weeks after the immediately preceding dose.
10. The method of any one of claims 1 to 9, wherein an anti-CTLA-4 antibody or antigen-binding fragment thereof is administered before or after the bispecific antibody.
11. The method of any one of claims 1 to 10, wherein the anti-CTLA4 antibody or antigen-binding fragment thereof and / or the bispecific antibody is administered intravenously, subcutaneously, or intraperitoneally.
12. The method of any one of claims 1 to 11, further comprising administering to the subject a third therapeutic agent or therapy.
13. The third therapeutic agent or therapy is selected from the group consisting of radiation, surgery, chemotherapy, cancer vaccines, PD1 inhibitors, PD-L1 inhibitors, LAG-3 inhibitors, TIM3 inhibitors, BTLA inhibitors, TIGIT inhibitors, CD47 inhibitors, indoleamine-2,3-dioxygenase (IDO) inhibitors, vascular endothelial growth factor (VEGF) antagonists, angiopoietin-2 (Ang2) inhibitors, transforming growth factor beta (TGF.beta.) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, antibodies against tumor-specific antigens, Bacillus 13. The method of claim 12, wherein the therapeutic agent is selected from the group consisting of Calmette-Guerin vaccine, granulocyte-macrophage colony stimulating factor, cytotoxins, interleukin 6 receptor (IL-6R) inhibitors, interleukin 4 receptor (IL-4R) inhibitors, IL-10 inhibitors, IL-2, IL-7, IL-21, IL-15, antibody drug conjugates, anti-inflammatory drugs, and dietary supplements.
14. The method of any one of claims 1 to 13, wherein the anti-CTLA4 antibody or antigen-binding fragment thereof is selected from ipilimumab and REGN4659.
15. The method of any one of claims 1 to 13, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
34.
16. The method of claim 15, wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 35, HCDR2 comprises the amino acid sequence of SEQ ID NO: 36, HCDR3 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence of SEQ ID NO:
40.
17. The method of claim 16, wherein the anti-CTLA4 antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO:33 and an LCVR comprising the amino acid sequence of SEQ ID NO:
34.
18. The method of any one of claims 15 to 17, wherein the anti-CTLA-4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:41 and a light chain comprising the amino acid sequence of SEQ ID NO:
42.
19. 19. The method of any one of claims 1 to 18, wherein the first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
20. 20. The method of claim 19, wherein A-HCDR1 comprises the amino acid sequence of SEQ ID NO:8, A-HCDR2 comprises the amino acid sequence of SEQ ID NO:9, A-HCDR3 comprises the amino acid sequence of SEQ ID NO:10, A-LCDR1 comprises the amino acid sequence of SEQ ID NO:11, A-LCDR2 comprises the amino acid sequence of SEQ ID NO:12, and A-LCDR3 comprises the amino acid sequence of SEQ ID NO:
13.
21. The method of claim 20, wherein the bispecific antibody comprises an A-HCVR comprising the amino acid sequence of SEQ ID NO:1, and an A-LCVR comprising the amino acid sequence of SEQ ID NO:
2.
22. The method of any one of claims 1 to 21, wherein the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 4, 5, 6, and 7, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
23. 23. The method of claim 22, wherein B-HCDR1, B-HCDR2 and B-HCDR3 each comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-15-16, 17-18-19, 20-21-22, 23-24-25, and 26-27-28, and B-LCDR1, B-LCDR2 and B-LCDR3 each comprise an amino acid sequence of SEQ ID NOs: 11-12-13.
24. 24. The method of claim 23, wherein the bispecific antibody comprises a B-HCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 4, 5, 6, and 7, and a B-LCVR comprising the amino acid sequence of SEQ ID NO:
2.
25. The method of claim 22, wherein the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:3, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
26. 23. The method of claim 22, wherein the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:4, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
27. 23. The method of claim 22, wherein the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:5, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
28. 23. The method of claim 22, wherein the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:6, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
29. 23. The method of claim 22, wherein the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:7, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
30. 30. The method of any one of claims 1 to 29, wherein the anti-CTLA-4 antibody, the bispecific antibody, or both, comprise a human IgG1 or IgG4 heavy chain constant region.
31. 1. A method of treating or inhibiting the growth of a MUC16-expressing tumor, comprising administering to a subject in need thereof: (a) a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and (b) a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding arm that specifically binds MUC16 and a second antigen-binding arm that specifically binds CD3; (a) an anti-CTLA-4 antibody, or antigen-binding fragment thereof, comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 33, and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 34; (b) the first antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO:1, and three light chain CDRs (A-LCDR1, A-LCDR2, and A-LCDR3) of a light chain variable region (A-LCVR) comprising the amino acid sequence of SEQ ID NO:2; (c) the second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO:3, and three light chain CDRs (B-LCDR1, B-LCDR2, and B-LCDR3) of a light chain variable region (B-LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
32. (a) HCDR1 comprises the amino acid sequence of SEQ ID NO: 35, HCDR2 comprises the amino acid sequence of SEQ ID NO: 36, HCDR3 comprises the amino acid sequence of SEQ ID NO: 37, LCDR1 comprises the amino acid sequence of SEQ ID NO: 38, LCDR2 comprises the amino acid sequence of SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 40; (b) A-HCDR1 comprises the amino acid sequence of SEQ ID NO:8, A-HCDR2 comprises the amino acid sequence of SEQ ID NO:9, A-HCDR3 comprises the amino acid sequence of SEQ ID NO:10, A-LCDR1 comprises the amino acid sequence of SEQ ID NO:11, A-LCDR2 comprises the amino acid sequence of SEQ ID NO:12, and A-LCDR3 comprises the amino acid sequence of SEQ ID NO:13; (c) The method of claim 31, wherein B-HCDR1 comprises the amino acid sequence of SEQ ID NO: 14, B-HCDR2 comprises the amino acid sequence of SEQ ID NO: 15, B-HCDR3 comprises the amino acid sequence of SEQ ID NO: 16, B-LCDR1 comprises the amino acid sequence of SEQ ID NO: 11, B-LCDR2 comprises the amino acid sequence of SEQ ID NO: 12, and B-LCDR3 comprises the amino acid sequence of SEQ ID NO:
13.
33. (a) the anti-CTLA4 antibody, or antigen-binding fragment thereof, comprises the HCVR comprising the amino acid sequence of SEQ ID NO: 33, and the LCVR comprising the amino acid sequence of SEQ ID NO: 34; (b) the bispecific antibody comprises an A-HCVR comprising the amino acid sequence of SEQ ID NO:1, and an A-LCVR comprising the amino acid sequence of SEQ ID NO:2; (c) the bispecific antibody comprises a B-HCVR comprising the amino acid sequence of SEQ ID NO:3, and a B-LCVR comprising the amino acid sequence of SEQ ID NO:
2.
34. (a) the anti-CTLA-4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:41 and a light chain comprising the amino acid sequence of SEQ ID NO:42; (b) the first antigen-binding arm of the bispecific antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:30; (c) the second antigen-binding arm of the bispecific antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 31, and a light chain comprising the amino acid sequence of SEQ ID NO:
30.
35. The method of any one of claims 31 to 34, wherein the tumor comprises ovarian cancer.
36. 36. The method of any one of claims 1 to 35, wherein administration of the anti-CTLA4 antibody, or antigen-binding fragment thereof, and the bispecific antibody results in an increase in serum cytokine levels in the subject of 5% or less compared to an isotype control 4 hours after administration.
